Indium Not Yet Recruiting Phase 1 Trials for Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT05363111Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma